AU2007304439A1 - Treatment for non-alcoholic-steatohepatitis - Google Patents
Treatment for non-alcoholic-steatohepatitis Download PDFInfo
- Publication number
- AU2007304439A1 AU2007304439A1 AU2007304439A AU2007304439A AU2007304439A1 AU 2007304439 A1 AU2007304439 A1 AU 2007304439A1 AU 2007304439 A AU2007304439 A AU 2007304439A AU 2007304439 A AU2007304439 A AU 2007304439A AU 2007304439 A1 AU2007304439 A1 AU 2007304439A1
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- group
- aryl
- independently selected
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84925106P | 2006-10-04 | 2006-10-04 | |
| US60/849,251 | 2006-10-04 | ||
| US90411607P | 2007-02-28 | 2007-02-28 | |
| US60/904,116 | 2007-02-28 | ||
| PCT/EP2007/008627 WO2008040548A2 (en) | 2006-10-04 | 2007-10-04 | Treatment for non-alcoholic-steatohepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007304439A1 true AU2007304439A1 (en) | 2008-04-10 |
| AU2007304439A2 AU2007304439A2 (en) | 2009-04-23 |
Family
ID=38949734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007304439A Abandoned AU2007304439A1 (en) | 2006-10-04 | 2007-10-04 | Treatment for non-alcoholic-steatohepatitis |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080194575A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2157975A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010505783A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007304439A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2664413A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL197941A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008040548A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| US8524212B2 (en) * | 2007-10-24 | 2013-09-03 | Mitsubishi Tanabe Pharma Corporation | Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis |
| US20100008988A1 (en) * | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
| US20120202849A1 (en) * | 2009-10-12 | 2012-08-09 | Anil Pareek | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| AU2011260323A1 (en) | 2010-06-04 | 2012-11-15 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as LRRK2 modulators |
| KR101566091B1 (ko) | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| US8865641B2 (en) | 2011-06-16 | 2014-10-21 | The Feinstein Institute For Medical Research | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways |
| CA2848711C (en) * | 2011-09-16 | 2019-08-06 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| CA2941411A1 (en) * | 2014-03-21 | 2015-09-24 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
| CA2968215A1 (en) * | 2014-08-20 | 2016-02-25 | Yale University | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
| CN105267953B (zh) * | 2015-09-15 | 2018-08-31 | 浙江大学 | Dll4细胞因子在制备治疗暴发性肝功能衰竭药剂中的应用 |
| EP3445450A4 (en) * | 2016-04-21 | 2020-01-08 | CSL Limited | METHOD FOR TREATING OR PREVENTING LIVER DISEASES |
| US20170319540A1 (en) * | 2016-05-06 | 2017-11-09 | Vivus, Inc. | Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis |
| EP3278802A1 (en) * | 2016-08-04 | 2018-02-07 | Metabolys | New treatment for the non alcoholic steatohepatitis and fibrosis |
| GB201614455D0 (en) | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| TW201818964A (zh) * | 2016-09-30 | 2018-06-01 | 瑞士商諾伊曼特醫療公司 | 使用色胺酸羥化酶抑制劑之方法 |
| US20190351003A1 (en) * | 2017-02-07 | 2019-11-21 | The Regents Of The University Of California | Methods for inhibiting nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis |
| JPWO2020090967A1 (ja) * | 2018-10-31 | 2021-09-16 | 東和薬品株式会社 | 線維化誘導遺伝子の発現抑制剤およびその用途 |
| WO2021073643A1 (zh) * | 2019-10-18 | 2021-04-22 | 正大天晴药业集团股份有限公司 | 用于治疗非酒精性脂肪性肝炎的药物 |
| CN113087757A (zh) * | 2021-03-12 | 2021-07-09 | 济南大学 | 一种5α结构的乙型强心苷的制备及其抗肝癌应用 |
| KR102684334B1 (ko) * | 2021-08-18 | 2024-07-12 | 제이투에이치바이오텍 (주) | 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| WO2002085396A1 (en) * | 2001-04-24 | 2002-10-31 | President And Fellows Of Harvard College | Inhibition of jun kinase |
| CA2512879A1 (en) * | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| US20050266391A1 (en) * | 2004-01-15 | 2005-12-01 | Bennett Brydon L | Methods for preserving tissue |
| WO2007035703A1 (en) * | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
-
2007
- 2007-10-01 US US11/906,328 patent/US20080194575A1/en not_active Abandoned
- 2007-10-04 CA CA002664413A patent/CA2664413A1/en not_active Abandoned
- 2007-10-04 WO PCT/EP2007/008627 patent/WO2008040548A2/en not_active Ceased
- 2007-10-04 AU AU2007304439A patent/AU2007304439A1/en not_active Abandoned
- 2007-10-04 JP JP2009530804A patent/JP2010505783A/ja active Pending
- 2007-10-04 EP EP07846490A patent/EP2157975A2/en not_active Withdrawn
-
2009
- 2009-04-05 IL IL197941A patent/IL197941A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008040548A2 (en) | 2008-04-10 |
| CA2664413A1 (en) | 2008-04-10 |
| IL197941A0 (en) | 2009-12-24 |
| EP2157975A2 (en) | 2010-03-03 |
| WO2008040548A3 (en) | 2009-05-22 |
| US20080194575A1 (en) | 2008-08-14 |
| JP2010505783A (ja) | 2010-02-25 |
| AU2007304439A2 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007304439A2 (en) | Treatment for non-alcoholic-steatohepatitis | |
| KR102699958B1 (ko) | 엘라피브라노르와 같은 ppar 작용제 및 아세틸-coa 카르복실라아제 (acc) 저해제를 포함하는 조합 | |
| ES2959842T3 (es) | Combinación de un agonista de PPAR con un agonista de FXR | |
| DK2582683T3 (en) | TREATMENT OF Gout and Hyperuricemia | |
| Xu et al. | Canagliflozin ameliorates nonalcoholic fatty liver disease by regulating lipid metabolism and inhibiting inflammation through induction of autophagy | |
| RU2684106C2 (ru) | Фармацевтические комбинации | |
| CA2794798C (en) | Treatment of gout | |
| AU2018233975A1 (en) | Pharmaceutical compositions for combination therapy | |
| KR20160079124A (ko) | 동질접합성 가족성 과콜레스테롤증의 치료 | |
| US20200155650A1 (en) | Combination treatment of NAFLD and NASH | |
| TW201136916A (en) | New uses | |
| JP2015511632A (ja) | メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与 | |
| Ouyang et al. | A natural compound jaceosidin ameliorates endoplasmic reticulum stress and insulin resistance via upregulation of SERCA2b | |
| JP2009545547A (ja) | 鉄キレーターを使用した内分泌機能不全の処置 | |
| CN104039148A (zh) | 组合als疗法 | |
| WO2025158405A1 (en) | Methods of improving glycemic control with a menin inhibitor | |
| EP3784650B1 (en) | N-phenyl-n'-(4-{[6-(1h-imidazol-1-yl)-4-pyrimidinyl]amino}phenyl)urea derivatives as mct4 inhibitors for the treatment of cancer | |
| US20220273593A1 (en) | Compounds and compositions for treating kidney disease | |
| CN114401745A (zh) | 包含fxr激动剂的治疗 | |
| Gray et al. | NAD (P) H oxidase isoforms as therapeutic targets for diabetic complications | |
| KR20210015849A (ko) | 트로피펙소르 및 세니크리비록을 포함하는 조합물 | |
| AU2002366975B2 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
| TW202539665A (zh) | Fgfr4抑制劑與ppar促效劑之組合 | |
| US20130095059A1 (en) | Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 MAR 2009 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |